Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 748,953	$ 681,101
Marketable securities	7,939	0
Accounts receivable, net	76,868	4,722
Inventories	18,277	0
Prepaid expenses and other current assets	60,240	34,869
Total current assets	912,277	720,692
Investment in nonconsolidated entities	108,002	143,747
Property and equipment, net	6,107	7,011
Operating lease right-of-use assets	6,186	5,767
Intangible assets, net	29,513	23,926
Other assets	18,105	18,195
Total assets	1,080,190	919,338
Current liabilities:
Accounts payable	26,134	9,618
Accrued compensation and benefits	37,187	58,329
Accrued research and development liabilities	31,295	34,272
Operating lease liabilities, current portion	4,782	4,506
Deferred revenue, current portion	10,540	14,604
Other current liabilities	65,916	33,071
Total current liabilities	175,854	154,400
Term loan, net	0	437,337
Deferred royalty obligations, net	813,959	479,091
Operating lease liabilities, net of current portion	4,025	4,696
Deferred revenue, net of current portion	14,667	17,095
Other long-term liabilities	545	286
Total liabilities	2,858,609	2,376,950
Commitments and contingencies (Note 8)
Redeemable convertible noncontrolling interests	(445)	142
Stockholders’ equity (deficit):
Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 500,000,000 shares authorized; 198,759,831 shares issued and 191,162,659 shares outstanding as of June 30, 2025, 196,236,234 shares issued and 190,044,473 shares outstanding as of December 31, 2024	198	196
Treasury stock, at cost; 7,597,172 shares as of June 30, 2025; 6,191,761 shares as of December 31, 2024	(323,276)	(275,000)
Additional paid-in capital	1,980,805	1,903,155
Accumulated other comprehensive income	1	8
Accumulated deficit	(3,445,588)	(3,096,263)
Total BridgeBio stockholders' deficit	(1,787,860)	(1,467,904)
Noncontrolling interests	9,886	10,150
Total stockholders' deficit	(1,777,974)	(1,457,754)	[1]
Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit	1,080,190	919,338
2031 Notes
Current liabilities:
Notes, net	563,597	0
2029 Notes
Current liabilities:
Notes, net	739,874	738,872
2027 Notes
Current liabilities:
Notes, net	$ 546,088	$ 545,173

[1] The consolidated balances as of December 31, 2024 and 2023 are derived from the audited consolidated financial statements as of those dates.